Trial
NCT02562443
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Traws Pharma, Inc.
Collaborators
—
Condition
Myelodysplastic Syndrome
Intervention
rigosertib
Why stopped
Top line analysis indicated that the study had failed to achieve its primary endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-26